Publications by authors named "A Cambon-Thomsen"
There are global movements aiming to promote reform of the traditional research evaluation and reward systems. However, a comprehensive picture of the existing best practices and efforts across various institutions to integrate Open Science into these frameworks remains underdeveloped and not fully known. The aim of this study was to identify perceptions and expectations of various research communities worldwide regarding how Open Science activities are (or should be) formally recognised and rewarded.
View Article and Find Full Text PDFObjective: New genome sequencing techniques allow new approaches in medical genetics, in particular by facilitating the diagnosis of genetic diseases. However, their use also leads to unsolicited genetic findings being uncovered. This type of discovery raises ethical, legal and psychological considerations.
View Article and Find Full Text PDFArticle Synopsis
- A study investigated the role of tumor genomics in predicting recurrence risk for patients with localized clear-cell renal cell carcinoma (ccRCC) after surgery, using a large cohort of 943 cases.
- Researchers analyzed the mutation status of 12 genes, particularly focusing on von-Hippel Lindau (VHL) mutations, finding distinct groups with different disease-free survival rates.
- The results suggest that genomic profiling can help tailor adjuvant treatment decisions, with patients having only a VHL mutation possibly needing less aggressive therapy compared to those with additional mutations.
Background: The benefit of pharmacogenetic testing before starting drug therapy has been well documented for several single gene-drug combinations. However, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel has not been rigorously assessed.
Methods: We conducted an open-label, multicentre, controlled, cluster-randomised, crossover implementation study of a 12-gene pharmacogenetic panel in 18 hospitals, nine community health centres, and 28 community pharmacies in seven European countries (Austria, Greece, Italy, the Netherlands, Slovenia, Spain, and the UK).
Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim is to provide novel insights into biological mechanisms underlying sunitinib action.
View Article and Find Full Text PDF